Assessment of Chilbains Occuring During Covid-19 Infection

• Conditions: COVID; Skin Manifestations; Chilblains

• Registration Number: NCT04344119
• Lead Sponsor: Centre Hospitalier Universitaire de Nice

Brief Summary

Some patients infected by covid-19 develop skin manifestations. These manifestations are still not well known and there pathophysiology remain unclear. Among them, acral manifestation resembling to chilblains appears frequent and quite specific. The aim of this project is to better characterize the cutaneous manifestations occurring during Covid-19 infection with a special focus on chilblains. These acral manifestation could be due to a direct viral effect, but also to microthrombosis or vascularitis. Understanding the pathomechanisms involved could provide interesting clue for understanding not only the skin manifestations but also some of the other systemic symptoms associated to covid-19 infection. This study plan to characterize these acral manifestations by analyzing the clinical and dermoscopic patterns and to correlate them with the non-invasive vascular explorations but also immune and coagulopathy explorations that are done in the CHU of Nice in covid-19 patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-04
• Study Start: 2020-04-09
• Study First Submitted: 2020-04-09
• Study First Submitted QC: 2020-04-10
• Study First Posted: 2020-04-14
• Last Update Submitted: 2021-01-19
• Last Update Posted: 2021-01-20
• Primary Completion: 2021-04-30
• Study Completion: 2021-04-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• All patients with proven covid infection (using PCR, serum antibody or lung TDM) and presenting at least one cutaneous lesions that occurred during the infection.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical skin manifestations	3 months	Type and description of the skin manifestations with a special focus on patients with chilblains

Secondary Outcome Measures

Name	Time	Method
Histology and biological data	3 months	Data on Histology (HE staining and immunofluorescence) and on biology (blood cells counts, CRP and immune profile) will be collected in covid patient with skin manifestation
Non invasive vascular examination	3 months	Vascular examination will be performed by Capillaroscopy, laser-doppler or lung TDM if clinically required

Trial Locations

Locations (1)

CHU de Nice; 🇫🇷 Nice, France